Corvus Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -3.89%52.160.9%$2501.20m
JNJJohnson & Johnson 2.17%162.840.7%$1339.97m
MRKMerck & Co., Inc. 0.11%73.420.7%$1168.23m
BMYBristol-Myers Squibb Co. 1.94%57.421.0%$788.52m
LLYEli Lilly & Co. -1.40%242.161.1%$715.98m
ABBVAbbVie, Inc. 2.22%121.491.9%$606.73m
AZNAstraZeneca Plc 2.25%55.451.0%$301.84m
NVSNovartis AG 0.94%80.750.2%$177.63m
GSKGlaxoSmithKline Plc 1.53%41.880.2%$165.15m
DRNADicerna Pharmaceuticals, Inc. -0.17%38.190.3%$148.73m
VTRSViatris, Inc. 2.01%12.450.0%$145.57m
RPRXRoyalty Pharma Plc 1.43%38.190.1%$114.08m
BFRIBiofrontera, Inc. -2.34%4.170.0%$104.66m
RGENRepligen Corp. -6.16%246.706.7%$99.01m
NVONovo Nordisk A/S -0.06%107.020.1%$85.13m

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.